Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Asunto principal
Intervalo de año de publicación
1.
J Fam Pract ; 71(6): E13-E15, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35994758

RESUMEN

YES. Augmentation with second generation antipsychotics, especially aripiprazole and quetiapine, appears to be effective in patients with moderate-to-severe depression who have had a suboptimal response to a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor (strength of recommendation [SOR]: A, based on a systematic review of randomized controlled trials [RCTs] and an individual RCT). Augmenting antidepressant therapy with cariprazine, ziprasidone, or olanzapine also appears to improve depressive symptoms over the short term. All antipsychotics studied carried an increased likelihood of adverse effects that could lead to discontinuation (SOR: A, based on a systematic review of RCTs).


Asunto(s)
Antipsicóticos , Antipsicóticos/efectos adversos , Aripiprazol/efectos adversos , Benzodiazepinas , Depresión/tratamiento farmacológico , Humanos , Olanzapina/uso terapéutico , Fumarato de Quetiapina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...